The physical condition of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated rapidly progressive glomerulonephritis (RPGN) is at times too critical for physicians to undertake a renal biopsy. In such cases, physicians need to start treatments without determining the pathological features of the disease. However, the prevalent clinical practice guidelines for ANCAassociated RPGN in Japan do not necessitate the pathological findings in a renal biopsy for determining first-line treatments. The aim of this study was to assess the correlation between the pathological findings and the clinical guideline-based treatments of ANCA-associated RPGN.
The algorithm of treatment for anti-neutrophil cytoplasmic antibody (ANCA) -associated rapidly progressive glomerulonephritis (RPGN). The first-line therapy is determined by assessment of the clinical grade, age, and need for dialysis. Additional therapies are considered in case of continuation of disease activity (modified from reference 1). PSL, prednisolone; mPSL, methylprednisolone; CY, cyclophosphamide; IVCY, intravenous cyclophosphamide.
Assessment of clinical grade, age, and need for dialysis to suggest first-line therapies to physicians based on a patient's clinical score, which is determined by age, presence or absence of lung diseases, and serum levels of creatinine and C-reactive protein (CRP). After that, a second-line therapy can be determined on the basis of the therapeutic response to the first-line therapy. Hence, physicians do not necessarily have to undertake a renal biopsy when they use these clinical guidelines for the treatment of patients with ANCA-associated RPGN in critical conditions. In contrast, it is imperative for physicians to assess whether the guideline-based treatments are adequate for the severity of the pathological features in patients who could have undergone a renal biopsy.
Materials and Methods
We retrospectively examined patients who were admitted to our hospital to receive a percutaneous renal biopsy for the diagnosis and treatment of ANCA-associated RPGN.
We compared the clinical and pathological features of these patients in each treatment group.
Patients
We enrolled 29 patients with biopsy-proven crescentic glomerulonephritis and/or necrotizing vasculitis in our hospital. We excluded patients who were negative for ANCA or positive for anti-glomerular basement membrane antibodies. Finally, we enrolled 22 patients for analysis. All enrolled patients fulfilled the criteria for the Chapel Hill consensus conference definition of ANCAassociated vasculitis 2 . Furthermore, we treated all patients based on the clinical guidelines for ANCA-associated RPGN formulated by the JSN 1 ( Fig. 1) .
Informed Consent
In this study, we followed the retrospective observa- 
Grouping of the Patients
We retrospectively reviewed the medical records of the enrolled patients for their age, serum levels of creatinine and CRP, and presence or absence of lung disease to determine the clinical grade described in the clinical practice guidelines 1 for ANCA-associated RPGN ( Table 1) .
We divided all patients into the following three groups 
Assessment of Pathological Features in Renal Biopsy

Samples
In this study, we reviewed renal biopsies, processed using normal techniques for light microscopy, obtained from patients, and recorded the total number of glomeruli and glomeruli demonstrating crescent formation.
Then, we calculated the crescent formation ratio (CFR) using the following equation:
CFR (%) = (the number of crescent formation glomeruli)/(the total number of glomeruli) × 100
Based on the classification system of ANCA-associated glomerulonephritis, proposed by Berden et al. 3 , the pathological glomerular features were categorized into four groups as follows: focal (!50% normal glomeruli); crescentic (!50% glomeruli with cellular crescents); mixed (<50% normal, <50% crescentic, and <50% globally sclerotic glomeruli); and sclerotic (!50% globally sclerotic glomeruli).
Survival Rate at 1 Year
One year after the treatment, we evaluated the number of patients who were dead or alive and estimated the survival rate in each treatment group.
Statistical Analysis
While continuous variables were compared using the unpaired t-test, categorical variables were compared using the Fisher's exact test. We considered P<0.05 as statistically significant.
Results
Distribution of the Clinical Grade in Each Treatment
Group
The number of patients in groups A, B, and C was seven, six, and nine, respectively. Each treatment group Table 3) .
Distribution of the Pathological Classification in Each Treatment Group
In this study, the number of patients with a focal type pathological classification was seven, two, and one in groups A, B, and C, respectively. The number of patients with a mixed type pathological classification was two in Fig. 2 Crescent formation ratio (CFR) (%) and serum creatinine levels in each treatment group. CFR in group A was significantly lower than that in group B. In addition, CFR in group A was significantly lower than that in group C, and CFR in group B was significantly lower than that in group C. The serum levels of creatinine in both groups A and B were significantly lower than that in group C. No significant difference was observed in the serum creatinine levels between groups A and B. 
CFR at Diagnosis and Serum Creatinine Levels at Baseline in Each Treatment Group
The median CFR (%; ±SD) in group A (8.7%±7.7%) was significantly lower than that in groups B (30.2%±15.7%; P <0.05) and C (71.3%±25.5%; P<0.0001). Furthermore, the median CFR in group B was significantly lower than that in group C (P<0.01; Table 5 ; Fig. 2a ).
The median serum creatinine levels (mg/dL; ±SD) in both groups A (2.03±0.96 mg/dL) and B (1.90±0.86 mg/ dL) were significantly lower than that in group C (4.30±
1.63 mg/dL); group A vs. group C, P<0.01; group B vs.
group C, P<0.01. We observed no significant difference in the serum creatinine levels between groups A and B (Table 5; Fig. 2b ).
Survival Rate at 1 Year in Each Treatment Group
In this study, the survival rate at 1 year was 85.7% (six of seven) in group A, 66.7% (four of six) in group B, and 77.8% (seven of nine) in group C ( Table 5) .
Discussion
Some studies have reported a correlation between the prognosis and the pathological features of ANCAassociated RPGN 4 12 , than those with a sclerotic type 8 12 . In this study, the survival rate at 1 year in group C was 77.8%, which compared favorably with those in groups A (85.7%) and B (66.7%) ( Table 5 ), whereas the ratio of patients with a crescentic type pathological classification in group C was significantly higher than those in groups A and B ( Table   4 ). These results indicate that patients with a crescentic type pathological classification could be treated with potent immunosuppressive agents and might exhibit a good prognosis, even though their CFRs were high at the time of diagnosis, if they followed the clinical practice guidelines used in Japan 1 . Moreover, our results revealed that patients intolerant to a renal biopsy could be treated adequately to the severity of the assumed glomerular pathological features if they followed the same guidelines.
Thus, we infer that these guidelines are useful for physicians to determine the management of the disease in patients presenting difficulties in undergoing a renal biopsy.
The treatment given to two of the grade III patients and that given to one of the grade I patients was not typical when compared with the recommended therapies These are the reasons why we administered only an oral intake of PSL to two of the grade III patients, while one of the grade I patients was treated by mPSL pulse therapy followed by oral intake of PSL and an administration of immunosuppressive agents ( Table 2) .
Finally, the degree of crescent formation correlated with the immunosuppressive factor in each treatment group. Based on the clinical practice guidelines, physicians could treat patients intolerant to renal biopsies in accordance with the severity of their assumed glomerular lesions because the guidelines do not mandate the pathological features in selecting the treatment. Of note, this study has the limitations of being a retrospective study and of having enrolled a small number of patients. However, to the best of our knowledge, this is the first report to assess the correlation between renal pathology and treatment in patients with ANCA-associated RPGN.
